



<https://cdphe.colorado.gov/tb-providers>

CDPHE TB Screening in LTC Guidelines

New Admissions

All new admissions, will receive a 2-step tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA) blood test and symptom screen. *Signs and symptoms* of active TB disease include: persistent cough for more than 3 weeks, night sweats, fever, unexplained weight loss, loss of appetite, hemoptysis, chills, fatigue and chest pain. IGRAs are recommended for persons who received the bacilli Calmette-Guerin (BCG) vaccine and anyone with a documented severe hypersensitivity reaction to the TST solution (e.g., ulceration or necrosis). In a 2-step TST, if the first TST is interpreted as negative, the second test will be placed 1 to 3 weeks after the first. If a documented negative TST result in the past 12 months is provided by the resident, it will be considered the first step, and only one step need be given. If the resident provides documentation of a negative two-step test or one IGRA which was performed in Colorado in the previous 6 months, it will be considered adequate. If the symptom screen is positive for respiratory disease, the resident will have a CXR and/or further medical evaluation and must receive medical clearance for TB disease before admission to the facility.